DocumentsDate added
CASE REPORT
Dokiparty Krupa Daniel*, Chithambaram Chandrasekaran, Ajith Mano Reginald Appavoo, Nagaveni Palanivelu, Naveen Bharathi Kumaresan, Valarmathi Sekar
Department of Anatomy, Southern Medical University, Guangzhou, P.R. China
Address reprint requests to
*Dr. D. Krupa Daniel,
Department of Anatomy, Southern Medical University,Guangzhou, P.R. China
Article citation: Dokiparty KD, Chandrasekaran C, Reginald Appavoo AM, Palanivelu N, Kumaresan NB, Sekar V. A case report on heteroclitic quadrate lobe of liver and its implications. J Pharm Biomed Sci 2015;5(12):973–975.Available at www.jpbms.info
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Abstract
The liver is the largest wedge-shaped gland in the human body. It is located in the upper right quadrant of abdomen, below the diaphragm, but a small portion extends into the upper left quadrant. Anatomically it is divided into right lobe and left lobes with its quadrate lobe and caudate lobe. But, in our routine dissections in our anatomy laboratory we have found with an abnormality the liver having an extra lobe besides the normal right lobe, left lobe, quadrate and caudate lobes. The extra lobe is located between the ligamentum teres and the normal quadrate lobe of the liver hence named as heteroclitic quadrate lobe of the liver.
KEYWORDS liver, quadrate lobe, caudate lobe, heteroclitic quadrate lobe, ligamentum teres
References
1.Aktan ZA, Savas R, Pinar Y, Arslan O. Lobe and segment anomalies of the liver. J Anat Soc India. 2001;50:15–6.
2.Chiba S, Suzuki T. A tongue-like projection of the left lobe in human liver, accompanied with lienorenal venous shunt and intrahepatic arterial anastomosis. Okajimas Folia Anatomica Japonica. 1991;68:51–66.
3.Sexon CC, Zeman RK. Correlation of computed tomography, sonography, and gross anatomy of the liver. Am J Radiol.1985;141:711–8.
4.Radin DR, Colletti PM. Agenesis of the right lobe of the liver. Radiol. 1987;164:639–42.
5.Sato N, Kawakami K, Matsumoto S, Toyonaga T, Ishimitsu T, Nagafuchi K, et al. Agenesis of the right lobe of the liver: report of a case. Surgery Today. 1998;28:643–46.
6.http://onlinelibrary.wiley.com/doi/10.1002/ar.1090530209/abstract.
7.Champetier J, Yver R, Letoublon J, Vigneau B. A general review of anomalies of hepatic morphology and their clinical implications. Anat Clin. 1985;7:285–99.
8.Kakitsubata Y, Kakitsubata S. Anomalous right lobe of the liver: CT appearance. Gastrointestinal Radiol. 1991;16:326–8.
9.https://en.wikipedia.org/wiki/Round_ligament_of_liver.
10.Chenglin W, Lin C, Ziqin Z, Tingting X, Heyu D, Qianhua D, et al. Accessory lobes of the liver: a report of 3 cases and review of the literature. Intractable Rare Dis Res. 2012;1:86–91.
11.Ito F, Ando H, Watanabe Y, Seo T, Murahashi O, Harada T, et al. An accessory lobe of the liver disturbing closure of the umbilical ring. Pediatr Surg Int. 1999;15:394–6.
12.Olinde HD, Boggs HW, Jr. Infarction of an accessory lobe of the liver. AMA Arch Surg. 1958;77:650–1.
13.Han S, Soylu L. Accessory liver lobe in the left thoracic cavity.Ann Thorac Surg. 2009;87:1933–4.
Source of funding: None.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents, and royalties through this collaborative research.
All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
CASE REPORT
Anil Aggarwal1*,Shyamakant Prasad2,Ashok Kumar3,Babita Ahlawat4,Bhawana Sethi5
1 Professor and Head, Department of ENT,Shyam Shah Medical College, Rewa,Madhya Pradesh, India
Senior Resident2 and Associate Professor,3 Department of ENT, SHKM GMC, Nalhar,Mewat, Haryana, India
4 Senior Resident, Department of Dentistry,SHKM GMC, Nalhar, Mewat, Haryana, India
5 Associate Professor, Department of Pathology, Faculty of Medicine & Health Sciences, SGT University, Budhera,Gurgaon, Haryana, India
Address reprint requests to
Dr. Ashok Kumar,
Associate Professor,Department of ENT, Flat No. 302; B-1 Block; Residential Campus, SHKM GMC, Nalhar,Mewat 122107, Haryana, India
Article citation: Aggarwal A, Prasad S, Kumar A, Ahlawat B, Sethi B. A rare presentation of sinonasal hemangiopericytoma-like tumour in frontoethmoidal sinus:a diagnostic challenge. J Pharm Biomed Sci 2015;05(12):984–987. Available at www.jpbms.info
ABSTRACT
Sinonasal hemangiopericytoma-like tumour (SHPCL) are rare vascular neoplasms derived from Zimmerman’s capillary pericytes. They originate in a paranasal sinus and extend into the nasal cavity secondarily. Hemangiopericytomas of soft tissue usually occur in the retroperitoneum or the thigh and are an uncommon finding in the nasal and paranasal sinuses. They occur most commonly in adults in the sixth and seventh decades of life and clinically mimic allergic polyps. These patients most commonly present with symptoms of epistaxis and nasal obstruction. Microscopically, these tumours demonstrate a vascular architecture,are composed predominantly of spindle cells, and lack nuclear or cytoplasmic pleomorphism,mitotic activity, haemorrhage or necrosis. These criteria include the presence or absence of mitotic figures, necrosis, anaplasia, and haemorrhage. The present case with early onset in fourth decade with predominantly orbital symptoms, minimal findings on nasal endoscopy and biopsy gives a diagnostic challenge. Treated with complete surgical excision and diagnosis was confirmed by immunohistochemistry reports as a rare SHPCL. Being a locally invasive tumour with very less propensity for metastasis or recurrence, two year of recurrence free endoscopic follow up is sufficiently justified it to be cured.
KEYWORDS sinonasal hemangiopericytoma-like tumour, hemangiopericytomas, glomangiopericytoma
REFERENCES
1. Li XQ, Hisaoka M, Morio T, Hashimoto H. Intranasal pericytictumors (glomus tumor and sinonasal hemangiopericytoma-like tumor): report of two cases with review of the literature. Pathol Int. 2003 May;53(5):303–08.
2. Theilgaard SA, Buchwald C, Ingeholm P, Kornum Larsen S, Eriksen JG, Sand Hansen H. Esthesioneuroblastoma: a Danish demographic study of 40 patients registered between 1978 and 2000. Acta Otolaryngol. 2003;123(3):433–9.
3. Thompson LD, Miettinen M, Wenig BM. Sinonasal-type hemangiopericytoma:a clinicopathologic and immunophenotypic analysis of 104 cases showing perivascular myoiddifferentiation. Am J Surg Pathol. 2003 Jun;27(6):737–49.
4. Thompson L, Fanburg-Smith J, Wenig B. Tumours of the nasal cavity and paranasal sinuses. Borderline and low malignant potential tumours of soft tissue. In Barnes L, Eveson JW, Reichart P, Sidransky D (eds.) World Health Organization (WHO) Classification of Tumours. IARC Press, Lyon, France: Pathology and Genetics of Head and Neck Tumours; 2005. pp. 43–4.
5. Kanazawa T, Nishino H, Miyata M, Kuriki K, Abe K, Ichimura K.Haemangiopericytoma of infratemporal fossa. J Laryngol Otol. 2001 Jan;115(1):77–9.
6. Angouridakis N, Zaraboukas T, Vital J, Vital V. Sinonasal hemangiopericytoma of the middle turbinate: a case report and brief review of the literature. B-ENT. 2007;3(3):139–43.
7. Dandekar M, McHugh JB. Sinonasal glomangiopericytoma: case report with emphasis on the differential diagnosis. Arch Pathol Lab Med. 2010 Oct;134(10):1444–9.
8. Taglialatela Scafati C, D’Antonio A, Taglialatela Scafati S, Scotto di Clemente S, Parascandolo S. Glomangiopericytoma of the pterygomandibular space: an unusual case. Br J Oral Maxillofac Surg. 2007 Dec;45(8):673–5.
9. Thompson LD. Sinonasal tract glomangiopericytoma (hemangiopericytoma). Ear Nose Throat J. 2004 Dec;83(12):807.
10. Gengler C, Guillou L. Solitary fibrous tumour and haemangiopericytoma:evolution of a concept. Histopathology. 2006 Jan;48(1):63–74.
11. Wilson T, Hellquist HB, Ray S, Pickles J. Intranasal myopericytoma. A tumour with perivascular myoid differentiation: the changing nomenclature for haemangiopericytoma. J Laryngol Otol. 2007 Aug;121(8):786–9.
12. Mosesson RE, Som PM. The radiographic evaluation of sinonasal tumors: an overview. Otolaryngol Clin North Am. 1995;28(6):1097–115.
13. Batsakis JG, Jacobs JB, Templeton AC. Hemangiopericytoma of the nasal cavity: electron-optic study and clinical correlations. J Laryngol Otol. 1983 Apr;97(4):361–8.
14. Nielsen GP, Dickersin GR, Provenzal JM, Rosenberg AE. Lipomatous hemangiopericytoma. A histologic, ultractural and immunohistochemical study of a unique variant of hemangiopericytoma. Am J Surg Pathol. 1995 Jul;19(7):748–56.
15. Gillman G, Pavlovich JB. Sinonasal hemangiopericytoma.Otolaryngol Head Neck Surg. 2004 Dec;131(6):1012–3.
16. Palacios E, Restrepo S, Mastrogiovanni L, Lorusso GD, Rojas R. Sinonasal hemangiopericytomas: clinicopathologic and imaging findings. Ear Nose Throat J. 2005 Feb;84(2):99–102.
17. Lin IH, Kuo FY, Su CY, Lin HC. Sinonasal-type hemangiopericytoma of the sphenoid sinus. Otolaryngol Head Neck Surg. 2006 Dec;135(6):977–9.
18. Weber W, Henkes H, Metz KA, Berg-Dammer E, Kühne D.Haemangiopericytoma of the nasal cavity. Neuroradiology. 2001 Feb;43(2):183–6.
19. Thiringer JK, Costantino PD, Houston G. Sinonasal hemangiopericytoma:case report and literature review. Skull Base Surg.1995;5(3):185–90.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Sources of funding: None.
Competing interest / Conflict of interest:
The author(s) have no competing interests for financial support, publication of this research, patents, and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Case report
Prafulla Govind Herode*, Abhijeet Shroof, Vinod Nair,Vishal Mandlewala, Amit Chaudhary
Department of Orthopaedics, Dr. D.Y Patil Medical College, Hospital and Research centre, Pimpri, Pune
Address reprint requests to
*Dr. Prafulla Govind Herode,
Associate Professor, Department of Orthopaedics, Dr. D.Y Patil Medical College, Hospital and Research centre, Pimpri, Pune 411108, India
Article citation: Herode PG, Shroof A, Nair V, Mandlewala V, Chaudhary A. A study of 50 cases of ankle fracture in adult treated with plating. J Pharm Biomed Sci 2015;05(12):936–940. Available at www.jpbms.info
Abstract:
Background Ankle fractures are one of the most common injuries treated by orthopaedic surgeons. On the basis of foot and the direction of the force many classification have been described, the most popular being that of Lauge Hansen. Management of this fracture depends on careful identification of extent of bony injury as well as soft tissue and ligamentous damage. In ankle fracture, operative treatment internal fixation with plate provides good result. So we decided to study the role of internal fixation in treatment of ankle fracture. Aims and Objectives To study the role of internal fixation with plate in treatment of ankle fracture with restoration of normal ankle function. Materials and Methods This is a prospective study of 50 cases of ankle fracture treated with open reduction and internal fixation with plate (1/3 tubular plate) at tertiary care teaching hospital carried out from May 2012 to July 2014. Criteria for assessment of quality of reduction used are the same as that of Burnwell and Charnley. Results Maximum patients belong to age group 21–40 (64%). Among them, 45 (90%) patients were male and 5 (10%) were females. Out of 50 patients treated, 30 (60%) patients obtained excellent results, 14 (28%) obtained good results and 6 (12%) had poor outcome. Conclusion The keyword of success is good anatomical reduction and rigid fixation of the fracture, irrespective of the classification of the fracture or the mode of injury.
KEYWORDS ankle fracture, internal fixation, open reduction, Lauge Hansen, Mortice view, anatomical reduction
REFERENCES
1.Lash N, Horne G, Fielden J, Devane P. Ankle fractures: functional and lifestyle outcomes at 2 years. ANZ J Surg. 2002;72:724–30.
2.Court-Brown CM, Caeser B. Epidemiology of adult fractures: review. Injury. 2006;37:691–7.
3.Bugler KE, White TO, Thordarson DB. Focus on ankle fractures. J Bone Surg. 2012;94:1107–112.
4.Daly PJ, Fitzgerald RH Jr, Melton LJ, Ilstrup DM. Epidemiology of ankle fractures in Rochester, Minnesota. Acta Orthop Scand. 1987;58:539–44.
5.Jensen SL, Anderson BK, Mencke S, Nielsen PT. Epidemiology of ankle fractures: a prospective population-based study of 212 cases in Aalborg, Denmark. Acta Orthop Scand. 1998;69:48–50.
6.Donken CCMA, Al-Khateeb H, Verhofstad MHJ, van Laarhoven CJHM. Surgical versus conservative intervention for treating ankle fractures in adults. The Cochrane Database of Systems Reviews; 2012. Published online. (http://dx.doi.org/10.1002/14651858. CD008470).
7.Michael P, Clare MD. A rational approach to ankle fractures. Foot and Ankle Clinic. 2008;13:593–610.
8.Gray’s Anatomy. 40th edition.
9.Bugler KE, White TO, Thordarson DB. Focus on ankle fractures. J Bone Surg. 2012;94:1107–112.
10.Burwell HN, Charnley AD. The treatment of displaced fractures at the ankle by rigid internal fixation and early joint movement. J Bone Joint Surg Br. 1965;47:634–59.
11.Phillips WA, Schwartz HS, Keller CS, et al. A prospective,randomized study of the management of severe ankle fractures. J Bone Joint Surg. 1985;67:67–8.
12.Joy G, Patzakis MJ, Harvey JP Jr. Precise evaluation of the reduction of severe ankle fractures. J Bone Joint Surg Am. 1974 Jul;56(5):979–93.
13.Salai M, Dudkiewicz L, Novikov I, Amit Y, Chechick A. The epidemic of ankle fractures in the elderly- is surgical treatment warranted? Arch Orthop Trauma Surg. 2000;120:511–3.
14.Lin CW, Donkers NA, Refshauge KM, Beckenkamp PR, Khera K, Mosseley AM. Rehabilitation for ankle fractures in adults. Cochrane Database Syst Rev. 2012;11.
15.Wei SY, Okereke E, Winiarsky R, Lotke PA. Nonoperatively treated displaced bimalleolar and trimalleolar fractures: a 20-year follow up. Foot Ankle Int. 1999;20:404–7.
16.Schaffer JJ, Manoli II, A. The antiglide plate for distal fibular fixation. a biomechanical comparision with fixation with a lateral plate. J Bone Joint Surg. 1987;69:596–604.
17.Minihane KP, Lee C, Ahn C, Zhang LQ, Merk BR. Comparison of lateral locking plate and antiglide plate for fixation of distal fibular fractures in osteoporotic bone: a biomechanical study. J Orthop Trauma. 2006;20:562–6.
18.Weber M, Krause F. Peroneal tendon lesions caused by antiglide plates used for fixation of lateral malleolar fractures: the effect of plate and screw position. Foot Ankle Int. 2005;26:281–5.
19.Lamontagne J, Blachut PA, Broekhuyse HM, O’Brien PJ, Meek RN. Surgical treatment of a displaced lateral malleolus fracture: the antiglide technique versus lateral plate fixation. J Orthop Trauma. 2002;16:498–502.
20.Arimoto P, Forrester DM. Classification of ankle fractures: an algorithm. Am J Roentgenol. 1980;125:1057–63.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents, and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Review Article:
Tesfamariam Alias, Natesan Gnanasekaran*
Department of Medical Biochemistry, School of Medicine, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia
Address reprint requests to
*Dr. N. Gnanasekaran,
Department of Medical Biochemistry, School of Medicine, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia
Article citation: Alias T, Gnanasekaran N. Role of endoplasmic reticulum in noncommunicable diseases. J Pharm Biomed Sci 2015;05(12):897–904. Available at www.jpbms.info
Abstract Endoplasmic reticulum (ER) is a large membrane-bound organelle that provides high fidelity quality control in protein synthesis, maturation and transport. There are two distinct types of ER that differ in structure and function: smooth ER and rough ER. The complex function of the ER can be significantly influenced by various factors both inside the cell and in its microenvironment. Disturbances in ER protein folding capacity result in accumulation of misfolded proteins in the ER lumen and in activation of ER stress. The unfolded protein response normally has pro-survival functions and protects cells by providing the reestablishment of protein processing and cellular homeostasis. However, prolonged and excessive ER stress results in activation of apoptotic pathways. Therefore, the persistent protein misfolding initiates apoptotic cascades that are now known to play fundamental roles in the pathogenesis of multiple human diseases including diabetes, atherosclerosis and neurodegenerative diseases. With the improved understanding of the underlying molecular mechanisms, therapeutic interventions that target the ER stress response would be potential strategies to treat various diseases driven by prolonged ER stress.
KEYWORDS ER stress, unfolded protein response (UPR), neurodegenerative disease,
liver disease, atherosclerosis, diabetes, cancer
REFERENCES
1.Albert B, Johnson A, Lewis J. Molecular biology of the cell. 5th edition. New York, NY: Garland Science; 2008.
2.Ozcan L, Tabas I. Role of endoplasmic reticulum stress in metabolic disease and other disorders. Annu Rev Med. 2012;63:317–28.
3.Back S, Kaufman H, Randal J. Endoplasmic reticulum stress and type 2 diabetes. Annu Rev Biochem. 2012;81:767–93.
4.Schonthal AH. Endoplasmic reticulum stress: its role in disease and novel prospects for therapy. Available from http://www. hindawi.com/journals/scientifica/2012/857516/.2012a.
5.Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol. 2007;8:519–29.
6.Schonthal AH. Targeting endoplasmic reticulum stress for cancer therapy. Front Biosci. 2012;4:412–31. Kim I, Xu W, Reed JC. Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat Rev Drug Discov. 2008;7:1013–30.
8.Liu CY, Xu Z, Kaufman RJ. Structure and intermolecular interactions of the luminal dimerization domain of human IRE1alpha. J Biol Chem. 2003;278:17680–7.
9.Credle JJ, FIner-Moore JS, Papa FR, Stroud RM, Walter P. On the mechanism of sensing unfolded protein in the endoplasmic reticulum. Proc Natl Acad Sci USA. 2005;102:18773–84.
10.Lin W, Kunkler PE, Harding HP. Enhanced integrated stress response promotes myelinating oligodendrocyte survival in response to interferon-gamma. Am J Pathol. 2008;173:1508–17.
11.Tabas I, Ron D. Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat Cell Biol. 2011;13:184–90.
12.Hummasti S, Hotamisligil G. Endoplasmic reticulum stress and inflammation in obesity and diabetes. Circulation Res. 2010;107:579.
13.Iwakoshi NN, Lee AH, Vallabhajosyula P, Otipoby KL, Rajewsky K, Glimcher LH. Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-I. NatImmunol. 2003;4:321–29.
14.Nawrocki ST, Carew JS, Pino MS. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stressmediated apoptosis. Cancer Res. 2005;65:11658–66.
15.Jager R, Bertrand MJ, Gorman AM. The unfolded protein response at the crossroads of cellular life and death during endoplasmic reticulum stress. Biol Cell. 2012;104:259–70.
16.Healy SJ, Gorman AM, Mousavi-Shafaei P, Gupta S, Samali A. Targeting the endoplasmic reticulum-stress response as an anticancer strategy. Eur J Pharmacol. 2009;625:234–46.
17.Kaufman R. The unfolded protein response. Nat Rev Mol Cell Biol. 2004;3:411–21.
18.Cullinan SB, Zhang D, Hannink M, Arvisais E, Kaufman RJ, Diehl JA. Nrf2 is a direct PERK substrate and effector of PERKdependent cell survival. Mol Cell Biol. 2003;23:7198–209.
19.Hoozemans JJ, Van Haastert ES, Nijholt DA, Rozemuller AJ, Eikelenboom P, Scheper W. The unfolded protein response is activated in pretangle neurons in Alzheimer’s disease hippocampus. Am J Pathol. 2009;174:1241–51.
20.Omura T, Kaneko M, Okuma Y, Orba Y, Nagashima K, Takahashi R, et al. A ubiquitin ligase hrd1 promotes the degradation of pael receptor, a substrate of Parkin. J Neurochem. 2006;99:1456–69.
21.Hotamisligil GS. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell. 2010;140:900–17.
22.Bobrovnikova-Marjon E, Grigoriadou C, Pytel D, Zhang F, Ye J,Koumenis C, et al. Perk promotes cancer cell proliferation and tumor growth by limiting oxidative DNA damage. Oncogene.2010;29:3881–95.
23.Auf G, Jabouille A, Guerit S, Pineau R, Delugin M, Bouchecareilh M, Magnin N, et al. Inositol-requiring enzyme 1alpha is a key regulator of angiogenesis and invasion in malignant glioma. Proc Natl Acad Sci USA. 2010;107:15553–8.
24.Fujimoto T, Yoshimatsu K, Watanabe K, Yokomizo H, Otani T,Matsumoto A, et al. Over expression of human x-box binding protein 1 (XBP-1) in colorectal adenomas and adenocarcinomas.Anticancer Res. 2007;27:127–31. Boden G. Endoplasmic reticulum stress: another link between obesity and insulin resistance/inflammation. Diabetes 2009;58:518–9.
26.Stankov K. Genetic predisposition for type 1 diabetes mellitus–the role of endoplasmic reticulum stress in human disease etiopathogenesis. J Med Biochem. 2010;29:139–49.
27.Gregor MF, Yang L, Fabbrini E. Endoplasmic reticulum stress is reduced in tissues of obese subjects after weight loss. Diabetes. 2009;58:693–700.
28.Groenendyk J, Agellon LB, Michalak M. Coping with endoplasmic reticulum stress in the cardiovascular system. Annu Rev Physiol. 2013;75:49–67.
29.Madonna R, de Caterina R. Relevance of new drug discovery to reduce NF-κB activation in cardiovascular disease. Vascular Pharmacol. 2012;57:41–7.
30.Okada K, Minamino T, Tsukamoto Y, Liao Y, Tsukamoto O,Takashima S, et al. Prolonged endoplasmic reticulum stress in hypertrophic and failing heart after aortic constriction: possible contribution of endoplasmic reticulum stress to cardiac myocyte apoptosis. Circulation. 2004;110:705–12.
31.Shintani-Ishida K, Nakajima M, Uemura K, Yoshida K. Ischemic preconditioning protects cardiomyocytes against ischemic injury by inducing GRP78. Biochem Biophys Res Commun.2006;345:1600–5.
32.Yoshida H. ER stress and diseases. FEBS J. 2007;274:630–58.
33.Bhandary B, Marahatta A, Kim H, Chae HJ. An involvement of oxidative stress in endoplasmic reticulum stress and its associated diseases. Int J Mol Sci. 2013;14:434–56.
34.Schonthal AH. Targeting endoplasmic reticulum stress for cancer therapy. Front Biosci. 2012b;4:412–31.
35.Boyce M, Yuan J. Cellular response to endoplasmic reticulum stress: a matter of life or death. Cell Death Differ. 2006;13:363–73.
36.Luo B, Lee AS. The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies. Oncogene. 2013;14:805–18.
37.Ozcan U, Yilmaz E, Ozcan L. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 2006;313:1137–40.
38.Ozcan L, Ergin AS, Lu A, Chung J, Sarkar S, Nie D, et al. Endoplasmic reticulum stress plays a central role in development of leptin resistance. Cell Metab. 2009;9:35–51.
39.Brown CD, Wang JF, Young LT. Regulation of ER stress proteins by valproate: therapeutic implications. Bipolar Disord. 2002;4:145–51.
40.Kudo T, Kanemoto S, Hara H. A molecular chaperone inducer protects neurons from ER stress. Cell Death Differ. 2008;15:364–75.
41.Cnop M, Ladriere L, Hekerman P, Ortis F, Cardozo AK, Dogusan Z, et al. Selective inhibition of eukaryotic translation initiation factor 2 alpha dephosphorylation potentiates fatty acid-induced endoplasmic reticulum stress and causes pancreatic beta-cell dysfunction and apoptosis. J Biol Chem. 2007;282:3989–97.
42.Nawrocki ST, Carew JS, Pino MS. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stressmediated apoptosis. Cancer Res. 2005;65:11658–66.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None.
Competing interest / Conflict of interest:
The author(s) have no competing interests for financial support, publication of this research, patents, and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Acknowledgements: The authors would like to thank Addis Ababa University College of Health Science, Department of Medical Biochemistry, for giving the opportunity to pursue education in Biochemistry. Their deepest gratitude and appreciation goes to their instructor Dr. N. Gnanasekaran for his unreserved help in writing this seminar paper and provision of valuable comments.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
ORIGINAL ARTICLE
Senior Resident,1 Associate Professor,3Senior Resident,4 and Professor & Head,7 Department of ENT, SHKM GMC, Nalhar,Mewat, Haryana, India
2 Professor and Head, Department of ENT, Shyam Shah Medical College, Rewa,Madhya Pradesh, India
5 Senior Resident, Department of Pediatric and Preventive Dentistry, Eklavya Dental College, Kotputli, Distt Jaipur, Rajasthan, India
6 Assistant Professor, Department of Psychiatry, SHKM GMC, Nalhar, Mewat, Haryana, India
Address reprint requests to
*Dr Ashok Kumar,
Associate Professor,Department of ENT, Flat no. 302, B-1 Block, Residential Campus, SHKM GMC,Nalhar, Mewat 122107, Haryana, India
Article citation: Prasad S, Aggarwal A,Kumar A, Ahlawat B, Chaudhary N, Rozatkar A, Naik SM. Acute invasive fungal rhinosinusitis: survival outcomes related to predefined parameters as variables. J Pharm Biomed Sci 2015;05(12):988–993.
ABSTRACT
The aim of this study was to determine outcomes and identify factors that may affect survival in patients with acute invasive fungal rhinosinusitis (AIFRS). Thirty patients of AIFRS were identified. The underlying reasons for immunosuppression were diabetes mellitus (19 patients), chronic renal failure (5 patients), leukemia (3 patients), acquired immunodeficiency syndrome (2 patients) and post organ transplant (1 patient).
We have found the overall survival rate directly related to AIFRS to be 56.7%. The survival rate is higher for young patients (below 50 years age group), diabetic patients than for patients with other causes of immunosuppression, sufferers of mucormycosis than aspergillosis and those treated with liposomal Amphotricsin B as compared to conventional form in addition to surgical debridements. Intracranial and orbital involvement and failure to recover are the factors that led to poor prognosis in this series.
KEYWORDS acute invasive fungal rhinosinusitis, absolute neutrophil count, mucormycosis, aspergillosis
REFERENCES
1. Plaignaud M. Observation surun fungus du sinus maxillare. J Chir. 1791;1:111–6.
2. de Shazo RD, O’Brien M, Chapin K, Soto-Aguilar M, Gardner L, Swain R. A new classification and diagnostic criteria or invasive fungal sinusitis. Arch Otolaryngol Head Neck Surg. 1997; 23(11):1181–8.
3. Feurguson BJ. Fungal rhinosinusitis. In: Cummings (eds): Otolaryngology Head and Neck Surgery, 5th ed. Philadelphia: Mosby Elsevier, 2010. pp. 709–10.
4. Klossek JM. Fungal rhinosinusitis. In: Michael G, et al (eds): Scott-Brown’s Otorhinolaryngology, Head and Neck Surgery. London,Great Britain: 2008. pp. 1454–5.
5. Gillespie MB, O’Malley BW, Francis HW. An approach to fulminant invasive fungal rhinosinusitis in the immunocompromised host. Arch Otolaryngol Head Neck Surg. 1998 May;124(5):520–6.
6. Talbot GH, Huang A, Provencher M. Invasive aspergillus rhinosinusitis in patients with acute leukemia. Rev Infect Dis. 1991 Mar–Apr;13(2):219–32.
7. Kennedy CA, Adams GL, Neglia JP, Giebink GS. Impact of surgical treatment on paranasal fungal infections in bone marrow transplant patients. Otolaryngol Head Neck Surg. 1997 Jun;116(6 Pt 1):610–16.
8. Sugar AM. Mucormycosis. Clin Infect Dis. 1992 Mar;14 Suppl 1:126–9.
9. Blitzer A, Lawson W. Fungal infections of the nose and paranasal sinuses. Part I. Otolaryngol Clin North Am. 1993 Dec;26(6):1007–35.
10. Fabiana CP, Valera. Prognosis of acute invasive fungal rhinosinusitis related to underlying disease. Int J Infect Dis. 2011;152:841–4.
11. Waitzman AA, Birt BD. Fungal sinusitis. J Otolaryngol. 1994 Aug;23(4):244–9.
12. Turner JH, Soudry E, Nayak JV, Hwang PH. Survival outcomes in acute invasive fungal sinusitis: a systematic review and quantitative synthesis of published evidence. Laryngoscope. 2013 May;123(5):1112–8.
13. McGill TJ, Simpson G, Healy GB. Fulminant aspergillosis of the nose and paranasal sinuses: a new clinical entity. Laryngoscope.1980 May;90(5 Pt 1):748–54.
14. Blitzer A, Lawson W, Meyer BR, Biller JF. Patient survival factors in paranasal sinus mucormycosis. Laryngoscope. 1980 Apr;90(4):635–48.
15. Blitzer A, Lawson W. Mycotic infections of the nose and paranasal sinuses. In: English G (ed): Otolaryngology. St. Louis, Mo: JB Lippincott, 1992. pp. 1–23.
16. Hora JF. Primary aspergillosis of the paranasal sinuses and associated areas. Laryngoscope. 1965 May;75:768–73.
17. Gillespie MB, O’Malley BW. An algorithmic approach to the diagnosis and management of invasive fungal rhinosinusitis in the immunocompromised patient. Otolaryngol Clin North Am.2000 Apr;33(2):323–34.
18. Weber RS, Lopez-Berestein G. Treatment of invasive Aspergillus sinusitis with liposomal-amphotericin B. Laryngoscope. 1987 Aug;97(8 Pt 1):937–41.
19. Milroy CM, Blandshard JD, Lucas S, Michaels L. Aspergillosis of the nose and paranasal sinuses. J Clin Pathol. 1989 Feb;42(2):123–7.
20. Levin LA, Avery R, Shore JW, Wooq JJ, Baker AS. The spectrum of orbital aspergillosis: a clinicopathological review. Surv Ophthalmol. 1996 Sep–Oct;41(2):142–54.
21. Parikh SL, Venkatraman G, Del Gaudio JM. Invasive fungal sinusitis: a 15-year review from a single institution. Am J Rhinol. 2004 Mar–Apr;18(2):75–81.
22. Sivak-Callcott J, Livesley N, Nugent RA, et al. Localised invasive sino-orbital aspergillosis: characteristic features. Br J Ophthmalmol. 2004;88:681–7.
23. Talmi YP, Goldschmied-Reouven A, Bakon M, Barshack I, Wolf M, Horowitz Z, et al. Rhino-orbital and rhino-cerebral mucormycosis. Otolaryngol Head Neck Surg. 2002;127(1):22–31.
24. Ochi JW, Harris JP, Feldman JI, Press GA. Rhinocerebral mucormycosis: results of aggressive surgical debridement and amphotericin B. Laryngoscope. 1988 Dec;98(12) 1339–42.
25. Stevens DA, Kan VL, Judson MA, Morrison VA, Dummer S,Denning DW, et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis. 2000 Apr;30(4):696–709.
26. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C,Bodensteiner D, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med. 1999 Mar;340(10):764–71.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Sources of funding: None.
Competing interest / Conflict of interest:
The author(s) have no competing interests for financial support, publication of this research, patents, and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.